Company intelligence / Profile preview
Shenzhen Celconta Life Science Co., Ltd.
Shenzhen, Guangdong, Chinaxkdbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Celconta Life has initiated a Phase 1 trial of an anti-Nectin‑4 CAR-T product for advanced breast cancer and another Phase 1 program targeting CLDN18.2-positive solid tumors. The company’s pipeline also includes preclinical and early clinical-stage programs focused on neurodegenerative diseases and gene therapies, with a strategic emphasis on expanding into orphan drug development and translational research.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCAR-NK cell therapyiT-cell therapy (CAR-iT)PANK cell therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Shenzhen Celconta Life Science Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Celconta Life Science Co., Ltd..